Loading...

Wright Medical Group

DB:T98
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
T98
DB
$3B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Wright Medical Group N.V., a medical device company, designs, manufactures, markets, and sells upper and lower extremities, and biologics products in the United States, Europe, the Middle East, Africa, Canada, Asia, Australia, and Latin America. The last earnings update was 72 days ago. More info.


Add to Portfolio Compare Print
T98 Share Price and Events
7 Day Returns
4.3%
DB:T98
-2.3%
DE Medical Equipment
-1.1%
DE Market
1 Year Returns
15.1%
DB:T98
6%
DE Medical Equipment
-8.5%
DE Market
T98 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Wright Medical Group (T98) 4.3% -12.9% -0.8% 15.1% 25.1% 55.9%
DE Medical Equipment -2.3% -1.7% 3.4% 6% 108.2% 255.7%
DE Market -1.1% -0.4% -4% -8.5% 8.1% 9.4%
1 Year Return vs Industry and Market
  • T98 outperformed the Medical Equipment industry which returned 6% over the past year.
  • T98 outperformed the Market in Germany which returned -8.5% over the past year.
Price Volatility
T98
Industry
5yr Volatility vs Market

Value

 Is Wright Medical Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Wright Medical Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Wright Medical Group.

DB:T98 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 17 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:T98
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.87
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.871 (1 + (1- 25%) (34.23%))
1.063
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.06
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.063 * 5.96%)
6.56%

Discounted Cash Flow Calculation for DB:T98 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Wright Medical Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:T98 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.56%)
2020 84.95 Analyst x2 79.72
2021 156.00 Analyst x1 137.37
2022 156.00 Analyst x1 128.91
2023 156.11 Est @ 0.07% 121.05
2024 156.29 Est @ 0.12% 113.73
2025 156.52 Est @ 0.15% 106.88
2026 156.79 Est @ 0.17% 100.47
2027 157.09 Est @ 0.19% 94.46
2028 157.41 Est @ 0.2% 88.82
2029 157.74 Est @ 0.21% 83.52
Present value of next 10 years cash flows $1,054.93
DB:T98 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $157.74 × (1 + 0.23%) ÷ (6.56% – 0.23%)
$2,494.96
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,494.96 ÷ (1 + 6.56%)10
$1,321.09
DB:T98 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,054.93 + $1,321.09
$2,376.02
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,376.02 / 126.12
$18.84
DB:T98 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:T98 represents 0.89904x of NasdaqGS:WMGI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.89904x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 18.84 x 0.89904
€16.94
Value per share (EUR) From above. €16.94
Current discount Discount to share price of €24.40
= -1 x (€24.40 - €16.94) / €16.94
-44.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Wright Medical Group is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Wright Medical Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Wright Medical Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:T98 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.53
NasdaqGS:WMGI Share Price ** NasdaqGS (2019-07-19) in USD $27.14
Germany Medical Equipment Industry PE Ratio Median Figure of 10 Publicly-Listed Medical Equipment Companies 31.63x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Wright Medical Group.

DB:T98 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:WMGI Share Price ÷ EPS (both in USD)

= 27.14 ÷ -1.53

-17.76x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wright Medical Group is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • Wright Medical Group is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Wright Medical Group's expected growth come at a high price?
Raw Data
DB:T98 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -17.76x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
26.9%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 2.49x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.44x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Wright Medical Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Wright Medical Group's assets?
Raw Data
DB:T98 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $7.24
NasdaqGS:WMGI Share Price * NasdaqGS (2019-07-19) in USD $27.14
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.07x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.73x
DB:T98 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:WMGI Share Price ÷ Book Value per Share (both in USD)

= 27.14 ÷ 7.24

3.75x

* Primary Listing of Wright Medical Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Wright Medical Group is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Wright Medical Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Wright Medical Group has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Wright Medical Group expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Wright Medical Group expected to grow at an attractive rate?
  • Unable to compare Wright Medical Group's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Wright Medical Group's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Wright Medical Group's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:T98 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:T98 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 26.9%
DB:T98 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 9.9%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.6%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.3%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:T98 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:T98 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,396 1
2022-12-31 1,302 219 3
2021-12-31 1,187 249 -109 9
2020-12-31 1,069 201 -50 17
2019-12-31 962 107 -93 17
DB:T98 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 868 -52 -180
2018-12-30 836 -64 -169
2018-09-30 816 -68 -120
2018-07-01 792 -179 -118
2018-04-01 766 -189 -48
2017-12-31 745 -185 -65
2017-09-24 720 -66 -122
2017-06-25 707 50 -140
2017-03-26 698 33 -161
2016-12-25 690 38 -165
2016-09-25 664 -79 -226
2016-06-26 587 -168 -236

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Wright Medical Group is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Wright Medical Group's revenue is expected to grow by 9.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:T98 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from Wright Medical Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:T98 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31 0.52 0.52 0.52 1.00
2021-12-31 -0.21 0.25 -0.82 3.00
2020-12-31 -0.34 -0.06 -0.99 5.00
2019-12-31 -0.67 -0.47 -1.16 5.00
DB:T98 Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.53
2018-12-30 -1.50
2018-09-30 -1.11
2018-07-01 -1.12
2018-04-01 -0.46
2017-12-31 -0.62
2017-09-24 -1.17
2017-06-25 -1.35
2017-03-26 -1.56
2016-12-25 -1.60
2016-09-25 -2.21
2016-06-26 -2.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Wright Medical Group is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Wright Medical Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Wright Medical Group has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Wright Medical Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Wright Medical Group's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Wright Medical Group does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Wright Medical Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Wright Medical Group's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Wright Medical Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Wright Medical Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:T98 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 867.78 -179.65 586.42 62.22
2018-12-30 836.19 -169.30 570.36 59.14
2018-09-30 815.65 -119.51 541.45 55.54
2018-07-01 792.04 -117.80 533.64 53.70
2018-04-01 766.34 -48.14 525.94 51.58
2017-12-31 744.99 -64.94 516.22 50.12
2017-09-24 720.41 -121.79 500.66 50.78
2017-06-25 707.24 -140.38 499.08 51.27
2017-03-26 698.26 -161.45 513.05 50.83
2016-12-25 690.36 -164.93 509.66 50.51
2016-09-25 664.17 -226.08 485.65 51.40
2016-06-26 586.98 -236.03 441.80 48.49
2016-03-27 496.68 -231.30 377.32 44.34
2015-12-27 405.33 -237.36 348.48 39.34
2015-09-30 321.79 -253.17 302.80 31.00
2015-06-30 312.96 -240.17 279.72 27.38
2015-03-31 304.90 -256.45 276.57 26.22
2014-12-31 298.03 -240.50 255.65 24.96
2014-09-30 279.96 -268.74 257.21 24.02
2014-06-30 266.29 -343.59 257.34 23.59
2014-03-31 254.50 -305.55 235.92 22.65
2013-12-31 242.33 -280.17 217.89 20.31
2013-09-30 232.89 -143.31 205.66 18.52
2013-06-30 226.13 -22.90 182.94 16.43
2013-03-31 217.53 -8.73 158.08 14.05
2012-12-31 214.11 -3.39 148.50 13.91
2012-09-30 282.60 -3.87 179.50 16.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Wright Medical Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Wright Medical Group has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Wright Medical Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Wright Medical Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Wright Medical Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Wright Medical Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Wright Medical Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Wright Medical Group's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Wright Medical Group's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Wright Medical Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Wright Medical Group Company Filings, last reported 3 months ago.

DB:T98 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 913.26 1,104.51 161.52
2018-12-30 932.46 1,089.59 191.35
2018-09-30 958.50 1,101.51 694.90
2018-07-01 568.24 1,101.86 313.21
2018-04-01 583.18 910.86 138.05
2017-12-31 588.70 895.11 167.74
2017-09-24 538.52 875.66 238.87
2017-06-25 634.63 831.41 228.88
2017-03-26 655.22 814.58 235.98
2016-12-25 686.86 814.36 262.27
2016-09-25 745.11 773.45 314.31
2016-06-26 842.37 761.47 326.25
2016-03-27 1,022.40 572.53 121.40
2015-12-27 1,055.03 563.37 139.80
2015-09-30 113.97 554.14 254.44
2015-06-30 211.18 547.38 427.87
2015-03-31 247.06 540.74 465.25
2014-12-31 278.80 281.33 229.90
2014-09-30 382.91 282.91 276.18
2014-06-30 441.80 280.33 315.14
2014-03-31 489.92 277.65 353.10
2013-12-31 459.71 275.40 175.43
2013-09-30 563.21 264.94 279.18
2013-06-30 686.40 262.75 287.27
2013-03-31 699.61 260.60 279.49
2012-12-31 523.44 258.49 333.01
2012-09-30 514.88 257.45 317.62
  • Wright Medical Group's level of debt (124%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (56.7% vs 124% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Wright Medical Group has sufficient cash runway for 1.1 years based on current free cash flow.
  • Wright Medical Group has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 20.3% each year.
X
Financial health checks
We assess Wright Medical Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Wright Medical Group has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Wright Medical Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Wright Medical Group dividends. Estimated to be 0% next year.
If you bought €2,000 of Wright Medical Group shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Wright Medical Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Wright Medical Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:T98 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:T98 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Wright Medical Group has not reported any payouts.
  • Unable to verify if Wright Medical Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Wright Medical Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Wright Medical Group has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Wright Medical Group's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Wright Medical Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Wright Medical Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Wright Medical Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Wright Medical Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bob Palmisano
COMPENSATION $6,376,447
AGE 74
TENURE AS CEO 7.8 years
CEO Bio

Mr. Robert J. Palmisano, also known as Bob, has been the Chief Executive Officer, President and Executive Director of Tornier N.V. since October 1, 2015. Mr. Palmisano has been the Chief Executive Officer, President and Executive Director of Wright Medical Group N.V. since September 17, 2011. Mr. Palmisano has been the Chief Executive Officer and President of Wright Medical Technology, Inc. since September 2011. He is a Venture Partner at SV Health Investors, LLC. He joined SV Health Investors in November 2007. He served as the Chief Executive Officer and President of Wright Medical Group Inc. since September 17, 2011. He served as the Chief Executive Officer and President of ev3 Inc. from April 6, 2008 to July 2010. He served as the Chief Executive Officer of Summit Autonomous, Inc. from April 1997 to 2000. He joined in this position in November 2007 and is focussed on medical devices sector. He served as the President and Chief Executive Officer of Intralase Corp., from April 2003 to May 2007, MacroChem Corp., from April 2001 to April 10, 2003 and Summit Technology Inc., from April 1997 to January 2001. From April 2001 to April 2003, he was the President, the Chief Executive Officer and a director of MacroChem Corporation. Mr. Palmisano served as a Senior Vice President and President of the Eyewear Division of Bausch & Lomb Incorporated from 1988 to 1996. He had a long history with Bausch & Lomb with various executive positions from 1985 to 1996. He held various positions of increasing responsibility with International Playtex Inc., Dunkin' Donuts and Mobil Oil Corp. From January 1997 to April 1997, he served as a Private Consultant. He has been a Director of Wright Medical Technology, Inc. since 2011, Avedro, Inc. since May 14, 2014 and Wright Medical Group Inc, since September 17, 2011. He serves as a Director of OraMetrix, Inc., iTherapeutix and LensX Lasers, Inc. Mr. Palmisano serves as a Director of Osteotech, Inc. since March 1, 2005, Songbird Hearing Inc. since 2002 and Bausch & Lomb Incorporated since September 2009. He served as a Director of Summit Autonomous, Inc. since April 1997, ev3 Inc. since April 6, 2008, Abbott Medical Optics Inc. from May 2007 to February 26, 2009, Intralase Corp., from April 2003 to May 2007, Summit Technology Inc., from April 1997 to January 2001 and MacroChem Corp., from April 2001 to April 10, 2003. He is on the Providence College Board of Trustees. He has significant experience leading public and private medical device companies. Mr. Palmisano holds an M.B.A. from Rutgers University and a BA in Political Science from Providence College.

CEO Compensation
  • Bob's compensation has increased whilst company is loss making.
  • Bob's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Wright Medical Group management team in years:

7.4
Average Tenure
53
Average Age
  • The average tenure for the Wright Medical Group management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Bob Palmisano

TITLE
President
COMPENSATION
$6M
AGE
74
TENURE
7.8 yrs

Lance Berry

TITLE
Executive VP
COMPENSATION
$2M
AGE
47
TENURE
9.6 yrs

Drew Morton

TITLE
Senior VP & Chief Human Resources Officer
COMPENSATION
$2M
AGE
53
TENURE
1.3 yrs

Kevin Cordell

TITLE
Executive VP & Chief Global Commercial Officer
COMPENSATION
$2M
AGE
53
TENURE
0.5 yrs

Peter Cooke

TITLE
President of emerging markets
COMPENSATION
$3M
AGE
54
TENURE
0.5 yrs

Julie Andrews

TITLE
VP & Chief Accounting Officer
AGE
48
TENURE
7.2 yrs

Jim Lightman

TITLE
Senior VP
COMPENSATION
$1M
AGE
61
TENURE
7.6 yrs

Jonathan Porter

TITLE
Senior VP & Chief Compliance Officer
AGE
49
TENURE
4.8 yrs

Tracy Dewey

TITLE
Senior VP & Chief Communications Officer
AGE
58
TENURE
7.8 yrs

Jennifer Walker

TITLE
Senior Vice President of Process Improvement
AGE
51
TENURE
7.6 yrs
Board of Directors Tenure

Average tenure and age of the Wright Medical Group board of directors in years:

10.5
Average Tenure
63
Average Age
  • The average tenure for the Wright Medical Group board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

David Stevens

TITLE
Chairman of The Board
COMPENSATION
$338K
AGE
65
TENURE
10.5 yrs

Bob Palmisano

TITLE
President
COMPENSATION
$6M
AGE
74
TENURE
7.8 yrs

Bess Weatherman

TITLE
Non-Executive Director
COMPENSATION
$321K
AGE
59
TENURE
13 yrs

John Miclot

TITLE
Non-Executive Director
COMPENSATION
$269K
AGE
60
TENURE
12.5 yrs

Gary Blackford

TITLE
Non-Executive Director
COMPENSATION
$273K
AGE
62
TENURE
11.5 yrs

Kevin O'Boyle

TITLE
Non-Executive Director
COMPENSATION
$273K
AGE
63
TENURE
3.8 yrs

Richard Wallman

TITLE
Non-Executive Director
COMPENSATION
$337K
AGE
68
TENURE
3.8 yrs

Amy Paul

TITLE
Non-Executive Director
COMPENSATION
$303K
AGE
67
TENURE
11.5 yrs

J. Mackin

TITLE
Non-Executive Director
COMPENSATION
$221K
AGE
52
TENURE
1.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Dec 18 Sell Patrick Fisher Individual 13. Dec 18 13. Dec 18 -9,000 €24.33 €-218,958
11. Dec 18 Buy Richard Wallman Individual 10. Dec 18 10. Dec 18 20,000 €23.60 €472,047
20. Nov 18 Sell Elizabeth Weatherman Individual 19. Nov 18 19. Nov 18 -2,640 €25.25 €-66,652
15. Aug 18 Sell Patrick Fisher Individual 13. Aug 18 13. Aug 18 -100 €24.52 €-2,452
X
Management checks
We assess Wright Medical Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Wright Medical Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Wright Medical Group N.V., a medical device company, designs, manufactures, markets, and sells upper and lower extremities, and biologics products in the United States, Europe, the Middle East, Africa, Canada, Asia, Australia, and Latin America. The company offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth. It also provides sports medicines and other products to mechanically repair tissue-to-tissue or tissue-to-bone injuries, as well as other ancillary products. The company primarily offers its products to orthopedic, trauma, and podiatric surgeons. It markets and sells its products through direct sales representatives, independent sales agencies, direct sales offices, and distributors. The company was founded in 1999 and is headquartered in Amsterdam, the Netherlands.

Details
Name: Wright Medical Group N.V.
T98
Exchange: DB
Founded: 1999
$3,022,435,866
126,122,077
Website: http://www.wright.com
Address: Wright Medical Group N.V.
Prins Bernhardplein 200,
Amsterdam,
Noord-Holland, 1097 JB,
Netherlands
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS WMGI Ordinary Shares Nasdaq Global Select US USD 10. Feb 2011
DB T98 Ordinary Shares Deutsche Boerse AG DE EUR 10. Feb 2011
BMV WMGI N Ordinary Shares Bolsa Mexicana de Valores MX MXN 10. Feb 2011
Number of employees
Current staff
Staff numbers
2,894
Wright Medical Group employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/19 21:23
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2019/07/15
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.